Triple-negative breast cancer

Investigating potential molecular therapeutic target

Anselmo Papa, Davide Caruso, Silverio Tomao, Luigi Rossi, Eleonora Zaccarelli, Federica Tomao

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Introduction: Triple-negative breast cancer (TNBC) makes up about 10-20% of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis.

Areas covered: In this review we investigated the molecular alteration present in TNBC which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way.

Expert opinion: In this context some hormone receptors like G-protein-coupled receptor 30 and androgen receptors may be a fascinating area to investigate; also, angiogenesis, represented not only by the classical VEGF/VEGFR relationship, but also by other molecules, like semaphorins, fibroblast growth factor and heparin-binding-EGF-like, is a mechanism in which new developments are expected. In this perspective, one technique that may show promise is the gene therapy; in particular the gene transfer could correct abnormal genetic function in cancer cells.

Original languageEnglish
Pages (from-to)55-75
Number of pages21
JournalExpert Opinion on Therapeutic Targets
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Tumors
Neoplasms
Semaphorins
Hormones
Breast Neoplasms
Gene transfer
Gene therapy
Fibroblast Growth Factors
Expert Testimony
Androgen Receptors
Therapeutics
G-Protein-Coupled Receptors
Tumor Suppressor Genes
Oncogenes
Epidermal Growth Factor
Genetic Therapy
Vascular Endothelial Growth Factor A
Heparin
Carcinogenesis

Keywords

  • Angiogenesis
  • Hormone receptors
  • Oncogene
  • Target therapy
  • Triple-negative breast cancer
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

Triple-negative breast cancer : Investigating potential molecular therapeutic target. / Papa, Anselmo; Caruso, Davide; Tomao, Silverio; Rossi, Luigi; Zaccarelli, Eleonora; Tomao, Federica.

In: Expert Opinion on Therapeutic Targets, Vol. 19, No. 1, 01.01.2015, p. 55-75.

Research output: Contribution to journalArticle

Papa, Anselmo ; Caruso, Davide ; Tomao, Silverio ; Rossi, Luigi ; Zaccarelli, Eleonora ; Tomao, Federica. / Triple-negative breast cancer : Investigating potential molecular therapeutic target. In: Expert Opinion on Therapeutic Targets. 2015 ; Vol. 19, No. 1. pp. 55-75.
@article{5e1679ff81c24cc9b84779d7610f99d1,
title = "Triple-negative breast cancer: Investigating potential molecular therapeutic target",
abstract = "Introduction: Triple-negative breast cancer (TNBC) makes up about 10-20{\%} of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis.Areas covered: In this review we investigated the molecular alteration present in TNBC which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way.Expert opinion: In this context some hormone receptors like G-protein-coupled receptor 30 and androgen receptors may be a fascinating area to investigate; also, angiogenesis, represented not only by the classical VEGF/VEGFR relationship, but also by other molecules, like semaphorins, fibroblast growth factor and heparin-binding-EGF-like, is a mechanism in which new developments are expected. In this perspective, one technique that may show promise is the gene therapy; in particular the gene transfer could correct abnormal genetic function in cancer cells.",
keywords = "Angiogenesis, Hormone receptors, Oncogene, Target therapy, Triple-negative breast cancer, Tumor suppressor gene",
author = "Anselmo Papa and Davide Caruso and Silverio Tomao and Luigi Rossi and Eleonora Zaccarelli and Federica Tomao",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14728222.2014.970176",
language = "English",
volume = "19",
pages = "55--75",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Investigating potential molecular therapeutic target

AU - Papa, Anselmo

AU - Caruso, Davide

AU - Tomao, Silverio

AU - Rossi, Luigi

AU - Zaccarelli, Eleonora

AU - Tomao, Federica

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Triple-negative breast cancer (TNBC) makes up about 10-20% of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis.Areas covered: In this review we investigated the molecular alteration present in TNBC which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way.Expert opinion: In this context some hormone receptors like G-protein-coupled receptor 30 and androgen receptors may be a fascinating area to investigate; also, angiogenesis, represented not only by the classical VEGF/VEGFR relationship, but also by other molecules, like semaphorins, fibroblast growth factor and heparin-binding-EGF-like, is a mechanism in which new developments are expected. In this perspective, one technique that may show promise is the gene therapy; in particular the gene transfer could correct abnormal genetic function in cancer cells.

AB - Introduction: Triple-negative breast cancer (TNBC) makes up about 10-20% of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis.Areas covered: In this review we investigated the molecular alteration present in TNBC which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way.Expert opinion: In this context some hormone receptors like G-protein-coupled receptor 30 and androgen receptors may be a fascinating area to investigate; also, angiogenesis, represented not only by the classical VEGF/VEGFR relationship, but also by other molecules, like semaphorins, fibroblast growth factor and heparin-binding-EGF-like, is a mechanism in which new developments are expected. In this perspective, one technique that may show promise is the gene therapy; in particular the gene transfer could correct abnormal genetic function in cancer cells.

KW - Angiogenesis

KW - Hormone receptors

KW - Oncogene

KW - Target therapy

KW - Triple-negative breast cancer

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=84918517845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918517845&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.970176

DO - 10.1517/14728222.2014.970176

M3 - Article

VL - 19

SP - 55

EP - 75

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -